Archives of Pharmaceutical Sciences and Research E-ISSN0975-2633 | PRINTISSN0975-5284
Vol 15 Issue 1 054–069 June 2025 Review Article

A COMPREHENSIVE REVIEW OF NOVEL APPROACHES FOR ANTI-INFLAMMATORY TREATMENT POST-CATARACT SURGERY

Prasad M Naik*, Usha G K , K Ramesh, Beny Baby

Department of Pharmaceutics, Karnataka College of Pharmacy, Bengaluru-560064

ABSTRACT

Cataract surgery, a widely performed ophthalmic procedure, is often accompanied by postoperative inflammation and complications due to anatomical and physiological barriers that hinder effective drug delivery. Conventional anti-inflammatory treatments face challenges in bioavailability, drug retention, and therapeutic efficacy. This review explores advanced nanoparticle-based drug delivery systems—including liposomes, niosomes, nanoemulsions, nanosuspensions, dendrimers, micelles, and cubosomes—that offer enhanced drug penetration, controlled and sustained release, and improved therapeutic outcomes. These nanocarriers effectively overcome ocular barriers, providing targeted delivery to affected tissues while minimizing systemic side effects and dosing frequency. By improving drug stability and optimizing recovery, they present promising solutions for postoperative cataract management. Additionally, nanoparticle-based formulations improve patient compliance and enable sustained drug release for long-term therapeutic benefits. Further research and development of these technologies are essential to refine their safety, efficacy, and adaptability for ophthalmic applications, ultimately advancing postoperative care and enhancing vision restoration in cataract patients.

KEYWORDS: Cataract surgery, postoperative inflammation, ocular drug delivery, nanoparticle-based systems, sustained drug release, bioavailability enhancement, therapeutic efficacy

INTRODUCTION

The eye, one of the most intricate sensory organs, keeps the body in touch with its environment by transmitting information to the brain through the optic nerve. Anterior ocular diseases are easy to treat with medication. Most posterior ocular diseases like macular degeneration, glaucoma, and diabetic retinopathies cannot be treated well due to the anatomical and physiological barriers of the eye, which pose difficult conditions for drug delivery and result in eventual loss of vision. A comprehensive understanding of these aspects is important for developing effective treatments for both anterior and posterior ocular diseases.[1]

Anatomy of the Human Eye

The Human Globe: The eye is a complex and highly specialized sensory organ essential for vision. Each eyeball, measuring approximately 24 mm in diameter and with a volume of 6.5–7 ml is housed in the eye socket and controlled by six muscles for movement. Anatomically, the eye is divided into anterior and posterior segments, making up one-third and two-thirds of its structure[2]. The anterior segment includes components like the cornea, iris, and lens, while the posterior segment contains the retina, optic nerve, and vitreous humor. Each structure has a distinct role, coordinating to form images and effectively enable vision.[3].

Anterior Segment: The anterior segment is the part of the eye that includes all the structures in front of the eye, which are very important for light focusing and ocular health.

Cornea: The cornea is composed of the following layers, listed from the outermost to the innermost:

1. **Epithelium**: The outermost layer, composed of epithelial cells, serves as a protective barrier against environmental damage and aids in maintaining the smooth surface of the cornea for proper light refraction.
2. **Bowman's Layer**: A tough, acellular layer that lies beneath the epithelium and provides structural support to the cornea.
3. **Stroma**: The thickest layer, primarily composed of organized collagen fibrils and extracellular matrix, which provides the cornea with its transparency and mechanical strength.
4. **Descemet's Membrane**: A thin but strong basement membrane located between the stroma and the endothelium, serving as a protective barrier.
5. **Endothelium**: The innermost layer, consisting of a single layer of cells responsible for maintaining corneal hydration by regulating fluid transport.

Each layer plays a vital role in maintaining the cornea's transparency and refractive properties, essential for clear vision.[4]

Conjunctiva: The conjunctiva is a mucous membrane lining the inner eyelids and covering the anterior surface of the eyeball, forming a sac between the eyelids and the globe. It connects with the skin at the eyelid margin and the cornea

at the limbus. The conjunctiva provides physical protection, secretes mucus for the tear film, and supports the mucosal immune system. Structurally, it comprises two main layers: the epithelium and underlying stroma. The epithelium varies regionally and contains goblet cells that produce mucus. The stroma consists of connective tissue, blood vessels, lymphatics, and immune cells, supporting vision and ocular health.[5]

Aqueous Humor: The aqueous humor is a clear fluid located in the anterior and posterior chambers of the eye, playing a crucial role in maintaining intraocular pressure and nourishing avascular structures such as the cornea and lens. It is produced by the ciliary epithelium of the ciliary body, where it first enters the posterior chamber before flowing through the pupil into the anterior chamber. From there, it drains out through the trabecular meshwork and Schlemm's canal, eventually reaching the venous system. This continuous circulation helps regulate intraocular pressure while ensuring the removal of metabolic waste from ocular tissues.[6]

Iris: The iris is a thin, pigmented, disc-like structure between the cornea and lens, regulating light entry by adjusting pupil size. It has two regions: the pupillary zone, forming the pupil's boundary, and the ciliary zone, extending toward the ciliary body. Structurally, it consists of the fibrovascular stromal layer, containing the sphincter pupillae and dilator pupillae muscles, and the epithelial layer, which is heavily pigmented to block excess light. The parasympathetic system controls constriction, while the sympathetic system controls dilation. These components work together to adjust pupil size in response to light and physiological conditions.[7]

Ciliary Body: Located behind the iris and has two major functions: 1. It produces aqueous humor to maintain ocular pressure and nourishment. 2. It enables accommodation by changing the shape of the lens through contraction and relaxation of its smooth muscles. Accommodation enables the eye to focus on objects at different distances.[1]

Lens: The lens of the eye is a transparent, flexible structure located behind the iris and the pupil. It is composed of tightly packed, elongated cells that lack nuclei, arranged in layers akin to an onion. The outer layer is called the lens capsule, which is non-cellular and supports the lens in position through zonules connected to the ciliary body. The lens consists of two main parts: the cortex (outer region) and the nucleus (central part). It plays a critical role in focusing light onto the retina by adjusting its shape, aided by the ciliary muscles during the process of accommodation.[8]

Posterior Segment:

The posterior segment is the part of the eye located at the back. It consists of parts that convert light into electrical signals and maintain the eye's structural integrity.

Sclera: The sclera is the outer supporting layer of the eye, extending from the limbus at the cornea's margin to the optic nerve, where it joins the Dural sheath of the optic nerve. It serves as a protective layer, helps maintain intraocular pressure, and provides attachment points for the extraocular muscles. The sclera's shape and thickness change over time, being thicker in early childhood and more rigid with age. It may experience focal thinning, leading to staphyloma, and scleral calcifications can form at the insertion sites of the rectus muscles. Additionally, the suprachoroidal space lies between the sclera and the choroid.[9]

Choroid: The choroid is the vascular and pigmented tissue of the middle eye layer, extending from the optic nerve to the ora serrata. Its inner surface is smooth and attaches to the retinal pigment epithelium (RPE), while the outer surface is rough and firmly connected to the sclera, particularly near the optic nerve, posterior ciliary arteries, ciliary nerve, and where the vortex veins exit. The choroid's attachment points contribute to the biconvex shape of choroidal detachment. Bruch's membrane, located between the retina and choroid, is involved in the growth of choroidal malignant melanoma when penetrated.[9]

Retinal Pigment Epithelium (RPE): The retinal pigment epithelium (RPE) is a monolayer of hexagonally packed cells extending from the ora serrata to the margin of the optic disk. In the area centralis, RPE cells measure approximately 16 µm in diameter. The cell density decreases from the fovea (about 4,000 cells/mm^2) to the peripheral fundus (about 1,600 cells/mm^2) and declines by about 0.3% per year with age. The apical surface of RPE cells features villous processes that interdigitate with photoreceptor

outer segments, while the basal surface has basilar infoldings. Tight junctions between cells form the outer blood-retinal barrier.[10]

Bruch's Membrane: Bruch's membrane is a thin structure that separates the retinal pigment epithelium (RPE) from the choriocapillaris. It is composed of five layers: the RPE basement membrane (innermost layer), the inner collagenous zone, the elastic fiber layer, the outer collagenous zone, and the basement membrane of the choriocapillaris (outermost layer). This membrane is PAS-positive and plays a critical role in maintaining the structural integrity of the retina and choroid. It facilitates the exchange of nutrients and waste between the retina and the choroid, ensuring proper retinal function.[10]

Neural Retina: The neural retina is a multilayered structure that transduces light into electrical impulses. It develops from the optic cup, a derivative of the diencephalon. The innermost layer contains ganglion cells, which form the optic nerve, while the outermost layer consists of rod and cone photoreceptors. Between these layers are the inner nuclear layer (containing horizontal, bipolar, and amacrine cells) and the outer nuclear layer (housing the photoreceptor nuclei). Synaptic connections form the outer plexiform layer (between photoreceptors and bipolar cells) and the inner plexiform layer (between bipolar and ganglion cells). The RPE supports photoreceptors and regulates nutrients.[11]

Vitreous Humor: The vitreous humor is a gel-like, highly hydrated tissue with 98%–99.7% water content, located between the lens and retina. It attaches to the retina, pars plana, and lens, with the strongest adhesion at the vitreous base. The inner limiting lamina (ILL) forms the retinal attachment surface.[12]

Optical Chambers: The optical chambers consist of three main regions likely anterior, posterior, and vitreous cavity. The anterior chamber is located between the cornea and iris which is filled with the aqueous humor. The posterior chamber is between the iris, zonule fibers, and lens and is filled with aqueous humor. The vitreous chamber is located between the lens and retina and is filled with vitreous humor.[1]

Extraocular Muscles: The extraocular muscles consist of six muscles: four rectus muscles (superior, inferior, lateral, medial) and two oblique muscles (superior and inferior). These muscles control eye movements, allowing for elevation, depression, adduction, and abduction of the eyeball. They are primarily innervated by the oculomotor nerve (CN III), abducens nerve (CN VI), and trochlear nerve (CN IV). The muscles insert circumferentially around the limbus of the eye, and their complex mechanical functions include primary actions and secondary/tertiary torsional movements. The anatomical arrangement enables coordinated movements for binocular vision and precise gaze control.[13]



Fig no.1 The Anatomy of the Human Eye.

Vascular Supply: The primary arterial supply for the globe and other components of the orbital cavity is the ophthalmic artery, which is a branch of the internal carotid artery. Both branches of the external carotid and ophthalmic arteries provide a dual circulatory supply to the conjunctiva and adnexal tissues, or the lids. [1]

Eyelids: The eyelids are thin, mobile fibro muscular folds that protect and lubricate the eyes. They consist of skin, subcutaneous tissue, the orbicularis oculi muscle for closure, the tarsal plate for support, and the conjunctiva lining the inner surface. The superior eyelid meets the eyebrow at the superior orbit palpebral sulcus, while the inferior eyelid transitions into the cheek. The palpebral fissure, bordered by the lid margins, allows vision. Key muscles include the levator palpebrae superioris for elevation and Müller's muscle for additional lift. Glands like the meibomian, Zeis, and Moll contribute to tear production and eye lubrication.[14]

The Lacrimal System: This system is composed of both a tear production and a tear drainage apparatus. The lacrimal system is the one responsible for tear production and drainage, consisting of two main components. The production apparatus includes the main lacrimal gland, which is located in the lacrimal fossa of the orbital roof and produces most of the tears, and the accessory lacrimal glands of Wolfring and Krause, found in the fornix of the superior eyelid, providing additional tear production. The draining apparatus provides efficient removal of tears from the ocular surface. It is initiated at the lacrimal puncta, tiny holes found inside the inner corners of the eyelids. The lacrimal sac is a small reservoir near the medial canthus of the eye. Tears, after passing from there, then drain into the inferior nasal meatus through the nasolacrimal duct.[15]

Physiology of the Human Eye:

Vision is the product of a complex interaction between light capture, image formation, signal transduction, and neural processing. Here is a general overview of the physiological process:

Light Capture and Refraction: Light enters the eye through the cornea, which bends (refracts) the light rays to focus them. The lens further adjusts its shape to fine-tune the focus, ensuring the light converges precisely on the retina. The iris regulates the amount of light entering the eye by controlling the size of the pupil.[1]

Image Formation: The cornea and lens together focus light onto the retina, creating an inverted image of the object being viewed. This image is sharpest at the fovea, a small, central region of the retina specialized for high-acuity vision.[4]

Signal Transduction: Photoreceptors in the retina absorb light and change it into electrical signals. This process involves a cascade of chemical reactions, collectively referred to as phototransduction. The signals travel up to bipolar cells, ganglion cells, and then to the optic nerve.[1]

Neural Processing: The optic nerve takes the visual information back into the brain; the visual cortex processes this information, and the brain uses these signals to produce coherent three-dimensional images.[1]

PATHOLOGY OF CATARACT:

Definition and Classification: Cataract is a common eye condition that causes clouding of the natural lens, leading to blurred or impaired vision. It occurs due to the accumulation of proteins in the lens, reducing the amount of light that reaches the retina. Cataracts typically develop gradually and can affect one or both eyes. They are a major cause of blindness worldwide, especially among older adults. The condition can significantly impact daily activities, making reading and driving difficult.[16]

Age-related Cataracts: Age-related cataract (ARC) is a common eye condition characterized by the progressive clouding of the lens, primarily due to aging. It is the most prevalent form of cataract and is a leading cause of vision impairment and blindness in the elderly. An age-related cataract occurs when changes related to aging affect the structure and composition of lens proteins, leading to increased opacification and diminished transparency of the lens.[16]

Type of age-related cataract:

Cortical Cataracts: Cortical cataracts are a common type characterized by the formation of wedge-shaped opacities that begin at the outer cortex of the lens and progress inward, resembling spokes on a wheel. This form of cataract typically develops with age but can also be influenced by factors such as diabetes, prolonged UV exposure, smoking, and certain medications.

Visual symptoms associated with cortical cataracts include glare, difficulty seeing in low

light, and blurred vision, which can affect distance and near vision. Patients may find daily activities like reading and driving increasingly challenging, particularly in dim conditions.

Cortical cataracts can coexist with other cataract types, such as nuclear and posterior subcapsular cataracts. When vision impairment becomes significant, surgical intervention is often required to remove the opacified lens and replace it with an intraocular lens, thereby restoring clearer vision.[17]

Diabetic Cataract: Diabetic cataract is a common complication of diabetes, occurring due to chronic hyperglycemia that leads to biochemical changes in the eye's lens. High glucose levels cause sorbitol accumulation, oxidative stress, and protein glycation, resulting in lens opacification. Diabetic patients have a 2–5 times higher risk of developing cataracts at a younger age, with faster progression than non-diabetics. Both type 1 and type 2 diabetes increase the likelihood of cortical and posterior subcapsular cataracts (PSC). Proper glycemic control, regular eye check-ups, and early intervention are crucial in preventing or delaying cataract formation in diabetic individuals.[16]

Nuclear cataract: Nuclear cataract is a common type of age-related cataracts that forms in the central zone, or nucleus, of the lens. This condition arises due to the aggregation and chemical changes of lens proteins (crystallins), leading to increased density and a yellowish coloration of the lens. Symptoms typically include blurred vision, difficulty with night vision, and alterations in color perception. Interestingly, some individuals may initially experience improved near vision, known as "second sight," before symptoms worsen. The primary risk factor is advancing age, but other contributing factors include diabetes, UV exposure, smoking, and heavy alcohol consumption. Treatment for nuclear cataracts involves surgical removal of the cloudy lens, followed by the implantation of an artificial intraocular lens (IOL) to restore vision. Given its prevalence in older populations, nuclear cataracts significantly impact visual health and quality of life[18]

Subscapular Cataract: A subcapsular cataract is a type of age-related cataract that forms just behind the anterior capsule or in front of the posterior capsule of the lens. Anterior subcapsular cataracts result from fibrous metaplasia of the lens epithelium, while posterior subcapsular cataracts occur due to epithelial cell migration. This type of cataract progresses rapidly, causing significant vision impairment, especially for near-vision tasks. Patients often experience glare sensitivity, particularly in bright light and while driving at night. A slit-lamp examination reveals a thin, plaque-like opacity. Among age-related cases, posterior subcapsular cataracts are more common and significantly affect visual acuity.[19]

Pediatric Cataracts: Often hereditary or caused by metabolic disorders, these cataracts can manifest at birth or during early childhood.[20]

Causes: Cataract formation is primarily caused **by** aging, oxidative stress, diabetes, genetics, and environmental factors**.**

1. **Aging** – The most common cause, leading to protein denaturation and accumulation of lens opacities over time.
2. **Oxidative Stress** – Free radicals damage lens proteins and lipids, reducing lens transparency. Antioxidant depletion (glutathione, ascorbate) accelerates this process.
3. **Diabetes & Metabolic Disorders** – Chronic hyperglycemia triggers sorbitol accumulation through the **polyol pathway**, causing osmotic stress, swelling, and oxidative damage.
4. **Genetic Factors** – Certain gene mutations affect lens protein stability, increasing susceptibility to cataract development.
5. **Environmental & Lifestyle Factors** – Prolonged **UV radiation exposure, smoking, and poor nutrition** contribute to cataract formation by inducing oxidative damage.
6. **Medications & Toxins** – Long-term use of **steroids, certain drugs, and toxic substances** can lead to cataracts.[21]

Symptoms: The symptoms of cataracts can vary depending on the type and progression of the condition. Common symptoms include:

1. **Blurred or Cloudy Vision**: One of the most prominent signs, making it difficult to see clearly.
2. **Difficulty with Night Vision**: Increased difficulty seeing in low-light conditions, making night driving challenging.
3. **Glare and Halos**: Sensitivity to light, often accompanied by halos around lights, particularly when driving at night.

4. **Faded or Yellowed Colors**: Colors may appear less vibrant or may have a yellowish tint.
5. **Double Vision**: Seeing multiple images in one eye (monocular diplopia), which can occur in advanced stages.
6. **Frequent Changes in Prescription**: The need for frequent updates to eyeglasses or contact lens prescriptions.
7. **Generalized Blurriness**: Vision may feel less sharp or focused overall.

As cataracts progress, these symptoms can worsen, significantly affecting day-to-day activities and quality of life.[18]



Chart no.1 Pathology of Cataract

Risk Factors and Etiology: The etiology of cataracts primarily revolves around various modifiable and non-modifiable risk factors that contribute to the development of this condition. According to the information in the document, key contributors include:

1. **Age**: Aging is the most significant non-modifiable risk factor, as the risk of developing cataracts increases with age.
2. **Lifestyle Factors**:
   - **Smoking**: There is a strong association between smoking and the development of cataracts.
   - **Alcohol Consumption**: Regular consumption of alcohol has been linked to an increased risk.
   - **Tobacco Chewing**: Similar to smoking, tobacco chewing contributes to cataract risk.
3. **Health Conditions**:
   - **Diabetes**: Patients with diabetes are at a significantly higher risk for developing nuclear and cortical cataracts.
   - **Hypertension**: While there is a relationship, the connection appears less strong compared to diabetes.
   - **Body Mass Index (BMI)**: Lower socioeconomic status and obesity are also noted as potential risk factors.
4. **Dietary Factors**:

Carotenoids: There is evidence suggesting that a higher intake of dietary antioxidants, specifically carotenoids like lutein, zeaxanthin, and β-carotene, may help reduce cataract risk,

5. **Genetic Factors**: These can also play a role, as familial tendencies for cataracts have been documented.

In essence, while aging remains the primary risk factor, lifestyle choices, health conditions, and dietary habits significantly influence the development and progression of cataracts. Understanding these factors is essential for developing effective prevention strategies for cataracts in various populations.[22]

Variables	**Subjects at risk, *n* (%)**	**Cataract *n* (%)**	
		Nuclear	**Cortical**
Age (years)			
45-54	940 (26.5)	71 (7.6)	19 (2)
55-64	1498 (42.2)	337 (22.4)	69 (4.6)
65-74	931 (26.2)	352 (37.8)	67 (7.2)
75+	180 (5.1)	78 (43.3)	7 (3.9)
Total	3549	838 (23.6)	162 (4.6)
Gender			
Male	2090 (58.9)	500 (23.9)	116 (5.5)
Female	1456 (41.1)	338 (23.2)	46 (3.2)
Residence			
Urban	2641 (74.4)	674 (25.5)	114 (4.3)
Rural	908 (25.5)	164 (18.1)	48 (5.2)
Socioeconomic status			
Lower	2065 (58.2)	318 (15.4)	88 (4.2)
Middle	958 (26.9)	425 (44.4)	52 (5.4)
Upper	518 (14.6)	95 (18.3)	22 (4.2)
Family size			
Small	1919 (54.1)	539 (28.1)	90 (4.7)
Medium	1481 (41.7)	271 (18.3)	66 (4.4)
Large	149 (4.2)	28 (18.8)	6 (4)
Education			
Illiterate	680 (19.2)	139 (20.4)	21 (3.1
School	1445 (40.7)	398 (27.5)	75 (5.2)
Undergraduate	682 (19.2)	189 (27.7)	30 (4.4)
Graduate	742 (20.9)	112 (15.1)	26 (3.5)

Table 1. Incidence of specific types of cataracts in the study population.[23]

Complications of cataract: Cataract surgery complications can occur intraoperatively, early, or late postoperatively. **Posterior capsule rupture**is the most common intraoperative issue, increasing risks of **retinal detachment and endophthalmitis**. **Postoperative corneal edema** may lead to **bullous keratopathy**, while **endophthalmitis** is the most severe complication. Preventive measures and timely treatments improve visual outcomes.[24]

Intraoperative complications: The intraoperative complications of cataract surgery include:

1. **Posterior Capsule Rupture**: This is the most common major complication during cataract surgery. It compromises the surgical procedure and can lead to more extensive postoperative complications.
2. **Vitreous Loss**: Often accompanying posterior capsule rupture, vitreous loss can lead to further complications, including retinal detachment and increased postoperative follow-up visits.
3. **Zonular Dialysis**: This condition involves the separation of the zonules (the fibers that hold the lens in place) from the lens, which can complicate the surgical procedure and affect the stability of the intraocular lens (IOL).
4. **Anterior Capsule Rupture**: This complication occurs when the anterior capsule of the lens is torn during the surgery, which can complicate IOL implantation and increase the risk of postoperative issues.
5. **Intraoperative Floppy Iris Syndrome (IFIS)**: This syndrome is associated with the systemic use of tamsulosin and can lead to a poorly dilated pupil, making it challenging for

the surgeon to visualize and manipulate the structures during surgery.

6. **Inadequate Mydriasis**: A small or poorly dilated pupil can hinder surgical visibility and increase the risk of complications such as posterior capsule rupture.
7. **Corneal Endothelial Damage**: Damage to the corneal endothelial cells can occur during surgery, especially when improper techniques or instruments are used. [25][26][27]

Early postoperative complications:

Early postoperative complications following cataract surgery are generally assessed during follow-up visits shortly after the procedure. According to the document, common early postoperative complications include:

1. **Anterior Uveitis**: This is an inflammation of the anterior part of the uveal tract and can present with symptoms such as eye redness and discomfort.
2. **Iris Incarceration**: This occurs when the iris becomes trapped in the surgical wound, which can lead to complications such as elevated intraocular pressure.
3. **Persistent Wound Leak**: This happens when there is inadequate closure of the surgical wound, potentially leading to eye fluid leakage. [25][28]

Postoperative complications:

Postoperative complications of cataract surgery can affect recovery and visual outcomes. Key postoperative complications include:

1. **Posterior Capsular Opacification (PCO)**: This is the most common late complication, occurring in about 25% of patients, where lens epithelial cells proliferate, leading to haze and vision impairment. It is usually treated with laser capsulotomy.
2. **Cystoid Macular Edema (CME)**: This condition involves swelling of the central retina (macula) and can occur due to inflammation post-surgery. CME may resolve spontaneously, but if it causes significant vision loss, it's managed with corticosteroids and non-steroidal anti-inflammatory medications.
3. **Increased Intraocular Pressure (IOP)**: Some patients may experience elevated IOP postoperatively due to inflammation or blockage of aqueous humor outflow. This can typically be managed with topical ocular-pressure-lowering agents.
4. **Endophthalmitis**: Although rare (approximately 0.08–0.10% of cases), this severe internal eye infection can lead to significant vision loss. It often requires immediate treatment with intravitreal antibiotics and, in some cases, vitrectomy.
5. **Retinal Detachment**: This serious complication occurs in approximately 2–3% of cases, especially in high myopes. It involves the retina separating from the underlying tissues, potentially leading to vision loss if not treated promptly.
6. **Uveitis**: Inflammation of the uveal tract can occur, leading to discomfort, increased IOP, and potential vision issues.[29][30]

Other risks and Complications:

Corneal Endothelial Cell Loss: Corneal endothelial loss is a potential complication of cataract surgery in children, similar to adults. Studies show a **decrease in endothelial cell count**, with **size variation and pleomorphism (shape variation)**observed post-surgery. A**9.2% endothelial cell loss** was recorded over 12 years, though its long-term impact remains unclear. No studies have assessed whether childhood cataract surgery leads to**corneal decompensation**in adulthood.[31]

Traumatic cataracts: Traumatic cataracts in children result from **ocular injuries**, posing a high risk of complications like **zonular instability, capsular holes, and vitreous loss**. Open-globe injuries often cause **corneal scarring, posterior synechiae, capsular tears, and iris distortion**. Many cases require **scleral-fixated IOLs** and **50% achieve good visual outcomes**, though **amblyopia is common**. Common causes include **paintballs, BBs, and pencils in the U.S., and bow and arrow injuries in rural India.**[31]

Management of Cataracts:

Surgical Removal: When a cataract leads to severe vision impairment the lens affected is removed surgically and replaced with the intraocular lens.

Post-operative care: topical steroids, antibiotics, or anti-inflammatory drugs are given 1-4 weeks are given post-operatively.[32]

Drugs used in treatment:

Nonsteroidal anti-inflammatory drugs (NSAIDs): They play a crucial role in managing ocular conditions, particularly during cataract surgery. They are primarily used to alleviate

pain, prevent intraoperative miosis, control postoperative inflammation, and decrease the likelihood of developing cystoid macular edema (CME).

The introduction of NSAIDs (nonsteroidal anti-inflammatory drugs) into ophthalmic practice has significantly enhanced surgical outcomes, particularly for patients who may face complications from corticosteroids, such as those with diabetes or herpetic keratitis. Effectively managing inflammation and pain during the perioperative period is crucial for both routine and complex cataract surgeries, making NSAIDs an important adjunct to these procedures.

NSAIDs represent a significant advancement in ocular surgery. They are a safe and effective alternative to corticosteroids for patients undergoing cataract procedures. [33]

Drug Name	Class	Indications in Cataract Post-Treatment
Diclofenac	Aryl Acetic Acid Derivative	Postoperative inflammation, prevention of cystoid macular edema (CME), pain relief
Ketorolac	Aryl Acetic Acid Derivative	Postoperative pain and inflammation, CME prevention, inhibition of prostaglandin-mediated inflammation
Nepafenac	Aryl Acetic Acid Derivative	Postoperative pain and inflammation, CME prevention (prodrug that converts to amfenac for enhanced efficacy)
Bromfenac	Aryl Acetic Acid Derivative	Postoperative inflammation and pain, potent COX-2 inhibition for longer duration of action
Flurbiprofen	Aryl Propionic Acid Derivative	Inhibition of intraoperative miosis, CME prevention
Suprofen	Aryl Propionic Acid Derivative	Inhibition of intraoperative miosis, postoperative inflammation
Piroxicam	Enolic Acid Derivative	Postoperative inflammation, inhibition of prostaglandin synthesis in glaucoma patients undergoing cataract surgery

Table No.2 NSAIDs used in the post-cataract management.[34][35]

Mechanism of Action: Nonsteroidal anti-inflammatory drugs (NSAIDs) primarily work by inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This inhibition reduces the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever. By decreasing prostaglandin levels, NSAIDs provide anti-inflammatory, analgesic, and antipyretic effects. In ocular applications, topical NSAIDs effectively penetrate eye tissues, managing inflammation and pain with minimal systemic absorption. Additionally, NSAIDs can enhance the effects of corticosteroids, further reducing inflammation and the risk of complications, such as cystoid macular edema, particularly in the context of cataract surgery[36]

Corticosteroids: Corticosteroids are integral to managing postoperative care in cataract surgery due to their powerful anti-inflammatory properties. Following cataract extraction, inflammation is a common response that can lead to complications such as pain, discomfort, and cystoid macular edema (CME), adversely affecting visual outcomes. The use of corticosteroids helps mitigate these inflammatory responses, promoting a smoother recovery and enhancing patient comfort. They can be administered in various forms, including topical drops, to target the ocular surface directly. By effectively controlling inflammation and preventing complications, corticosteroids are vital in optimizing surgical outcomes and improving overall patient satisfaction in cataract surgery.[37]

Drug Name	Formulation	Indications in Post-Cataract Treatment
Prednisolone acetate (Pred Forte, Econopred)	Topical (1% or 0.12%) suspension	Primary corticosteroid for post-cataract inflammation, widely used
Dexamethasone (Maxidex, Decadron)	Topical (0.1% solution), Intravitreal (Ozurdex implant)	Strong anti-inflammatory, also used for CME and uveitis
Fluorometholone (FML, Flarex)	Topical (0.1% or 0.25%) suspension	Milder corticosteroid for patients at risk of IOP rise
Rimexolone (Vexol)	Topical (1% suspension)	Reduces inflammation with lower risk of IOP increase
Loteprednol etabonate (Lotemax, Alrex)	Topical (0.5% suspension)	Soft steroid with fewer side effects, used for mild-to-moderate inflammation
Difluprednate (Durezol)	Topical (0.05% emulsion)	More potent than prednisolone, used for severe post-cataract inflammation
Triamcinolone acetonide (Kenalog, Triesence)	Subconjunctival, Intravitreal injection	Used for persistent inflammation and CME
Fluocinolone acetonide (Retisert, Iluvien)	Intravitreal implant	Used for chronic CME and uveitis

Table no.3 The corticosteroids used in post-cataract management.[38]

Mechanism of action: Corticosteroids exert their effects by binding to the glucocorticoid receptor (GR) in the cytoplasm, forming a steroid-receptor complex that translocates to the nucleus. It binds to glucocorticoid response elements (GREs) in DNA, regulating gene expression. This process upregulates anti-inflammatory proteins and downregulates pro-inflammatory cytokines and enzymes, such as COX-2. Additionally, corticosteroids inhibit transcription factors like NF-κB, reducing the expression of inflammatory genes. They also suppress the proliferation and activity of immune cells, leading to decreased inflammation and immune responses, making them potent anti-inflammatory agents in various medical conditions.[39]

Nanoparticles: Nanoparticles offer significant advantages in post-cataract surgery treatment by enhancing drug penetration, controlled release, and targeted delivery. They effectively bypass ocular barriers, improving the bioavailability of anti-inflammatory, antibiotic, and anti-fibrotic agents. Their sustained-release properties reduce the need for frequent administration, ensuring prolongedtherapeutic effects and better patient compliance. Additionally, site-specific drug delivery allows precise targeting of affected tissues, preventing complications such as inflammation and posterior capsular opacification.Functionalized nanoparticles, modified with ligands or antibodies, enable selective binding to inflammatory or fibrotic cells, enhancing therapeutic efficacy while minimizing systemic exposure and side effects, making them a promising innovation.[40]

Possible Novel Approaches for Anterior Ocular Disease:



Liposomes: Liposomes are advantageous for delivering drugs to treat anterior ocular diseases because they enhance drug permeability and bioavailability. They can significantly improve drug concentration in ocular tissues; for example, a liposomal formulation of triamcinolone acetonide showed a twofold increase in corneal and aqueous humor concentrations. Formulations like chitosan-coated ciprofloxacin and liposomes loaded with timolol maleate demonstrated longer retention times and greater trans-corneal permeation compared to conventional formulations. Commonly composed of phospholipids and cholesterol, liposomes present a promising approach for effective ocular drug delivery, improving therapeutic outcomes for various eye conditions.[41] [42].

Niosomes: Niosomes are non-ionic surfactant-based vesicles with significant potential for ocular drug delivery, particularly for anterior segment diseases. They enhance drug penetration by facilitating corneal absorption of hydrophilic and hydrophobic drugs. Their sustained-release mechanism maintains therapeutic drug levels, reducing dosing frequency and improving patient compliance. Niosomes enable targeted drug delivery, minimizing systemic side effects and enhancing treatment efficacy. Their biocompatibility ensures safety for ocular applications, while their versatility allows the encapsulation of various drugs, including anti-inflammatory and antiglaucoma agents. Overall, niosomes offer an advanced, effective approach for treating anterior ocular diseases with improved therapeutic outcomes and patient adherence.[43][44]

Nanosuspensions:

Nanosuspensions: They are colloidal dispersions of submicron drug particles stabilized by polymers or surfactants, offering a promising strategy for the ocular delivery of hydrophobic drugs. They enhance ocular bioavailability, increase precorneal residence time, and reduce irritation. Studies show improved bioavailability of glucocorticoids like prednisolone, dexamethasone, and hydrocortisone, reducing the need for frequent dosing, which can cause cataracts and glaucoma. Research in rabbit models demonstrated higher

drug absorption and prolonged effects with nanosuspensions compared to solutions. Additionally, nanosuspensions can be incorporated into hydrogels or ocular inserts for sustained drug release, making them an efficient ophthalmic drug delivery system.[45][46]

Nano Emulsion: Oil-in-water Nanoemulsions are an effective drug delivery system for topical ocular applications. They enhance drug transport by using non-ionic surfactants, which open tight junctions and inhibit P-glycoprotein (Pgp), improving drug penetration. Cationic surfactants help prolong drug retention through electrostatic interactions with the corneal epithelium, increasing bioavailability. Additionally, nanoemulsions integrate with the lipid layer of the tear film, allowing the drug to remain in the conjunctival sac for longer and acting as a sustained-release depot. Nanoemulsions improve ocular drug absorption, extend drug action, and enhance therapeutic effectiveness for better treatment outcomes.[47]

Cubosomes: Cubosomes offer a promising drug delivery system for managing anterior ocular diseases, including post-cataract surgery infections and inflammation. They enhance transcorneal permeability, ensuring better drug penetration into ocular tissues. Their prolonged retention on the ocular surface allows sustained drug release, reducing frequent dosing. Cubosomal formulations of ciprofloxacin and natamycin have shown superior antibacterial and antifungal activity, which can help prevent infections after cataract surgery. Additionally, cubosomes are biocompatible and non-irritating, making them safe for ocular application. By improving drug absorption and therapeutic efficacy, cubosomes are an advanced platform for preventing complications in cataract patients.[48]

Nano wafers: In the context of cataract treatment, nano wafers play a significant role by providing controlled drug release and prolonged drug retention on the ocular surface, enhancing drug absorption into anterior ocular tissues. They reduce the need for frequent dosing, offering a sustained release of therapeutic agents to treat post-surgery inflammation or infection. Nano wafers also serve as protective membranes for the corneal surface, aiding in the healing of post-cataract surgical wounds. With their ability to improve drug stability and anti-inflammatory effects, nano wafers enhance treatment efficacy, ensuring better patient compliance and therapeutic outcomes in cataract patients.[48]

Micelles: Micelles play a crucial role in anterior ocular drug delivery, especially post-cataract surgery, by enhancing drug solubility, penetration, and retention. They improve the bioavailability of hydrophobic drugs like dexamethasone and cyclosporine A, ensuring better inflammation control and infection prevention. Their small size (~10-100 nm) enables efficient corneal penetration, while sustained drug release reduces dosing frequency, improving patient compliance. Unlike traditional eye drops, micellar formulations reduce irritation and toxicity by eliminating harsh solvents. Examples include LX-214 for inflammation, moxifloxacin micelles for infections, and cyclosporine A micelles for dry eye post-cataract. Micelles enhance ocular therapy efficiency and patient outcomes.[49]

Dendrimers: In anterior ocular diseases, dendrimers play a crucial role in drug delivery by using their functional surface groups (amine, carboxyl, hydroxyl) to form electrostatic or covalent bonds with drugs, allowing controlled and targeted release. Their solubility and self-assembly properties enhance ocular penetration, ensuring that drugs reach deeper eye tissues. Additionally, dendrimers facilitate sustained drug release, reducing the need for frequent dosing and maintaining effective drug concentrations on the ocular surface. These characteristics make dendrimers an ideal platform for improving drug efficacy, bioavailability, and treatment outcomes in diseases like corneal infections or inflammation.[50]

Preparation Methods:

Nanoparticle: The sol-gel method is a well-established technique for synthesizing metal oxide nanoparticles and composites through hydrolysis, condensation, and drying. It begins with a metal precursor that undergoes rapid hydrolysis to form metal hydroxide, followed by condensation to create a gel. The gel is subsequently dried to yield xerogel or aerogel. This method can be aqueous or nonaqueous, allowing for control over the textural and surface properties of the resulting nanoparticles, although it may face challenges in controlling

particle morphology.[51][52]

Liposomes and Niosomes: The reverse-phase evaporation method for liposome preparation involves dissolving lipids in a volatile organic solvent to create an organic phase, which is then mixed with an aqueous drug solution to form a water-in-oil emulsion. The solvent is evaporated under reduced pressure, resulting in the encapsulation of the drug within lipid bilayers. This method allows for high encapsulation efficiency and flexibility in formulation, although careful control of the emulsion and solvent removal is necessary to prevent the degradation of sensitive components.

The thin-film hydration method involves dissolving surfactant and cholesterol in a volatile organic solvent, which is then evaporated using a rotary evaporator to create a thin film on the flask's wall. This dried layer is subsequently hydrated with an aqueous solution containing the drug of interest. The hydration process, conducted at room temperature with gentle agitation, forms niosomes as the surfactants self-assemble into vesicles around the aqueous phase. [53] [54] [55] [56] [57]

Nanosuspension: The supercritical fluid method utilizes supercritical fluids, such as carbon dioxide, at conditions above their critical temperature and pressure to dissolve and micronize drugs. This technique allows for efficient size reduction and nanosuspension formation by rapidly expanding the supercritical fluid, creating nanoparticles as the drug precipitates. While effective for achieving small particle sizes, the method may have limitations due to the solubility issues of drugs in supercritical fluids and the high pressures required for processing.[58] [59] [60]

Nano emulsion: The phase inversion method for preparing nanoemulsions involves altering the system's conditions to induce a change in emulsion type, typically between oil-in-water (O/W) and water-in-oil (W/O) configurations. It can proceed through phase inversion temperature (PIT) or phase inversion composition (PIC), whereby temperature or surfactant concentration changes trigger transformation. This method leverages the natural properties of surfactants, allowing for the formation of stable nanoemulsions without the need for significant external energy. [61] [62] [63]

Cubosomes: The top-down approach for cubosome preparation involves creating a viscous bulk cubic phase by mixing lipids with stabilizers to prevent aggregation. This bulk is then dispersed in an aqueous medium using high-energy methods such as sonication or high-pressure homogenization, resulting in the formation of cubosomes. This method effectively reduces particle size and maintains stability for up to a year, although it requires significant energy input, which may limit its use for temperature-sensitive drugs.[64] [65]

Nanowafers: The chemical co-precipitation method synthesizes nanoparticles by simultaneously precipitating metal salts from a solution using a base (e.g., NaOH, NH_4OH). Metal ions react to form hydroxides, which nucleate and grow into nanoparticles. Factors like pH, temperature, and stirring rate control size and shape. Surfactants stabilize particles, preventing agglomeration. After precipitation, the nanoparticles are separated by centrifugation or filtration, washed, and dried. This simple, cost-effective method is widely used in biomedical and industrial applications for magnetic nanoparticles, oxides, and composite materials.[66]

Micelles: The direct dissolution method is a simple technique for preparing drug-loaded polymeric micelles. It involves mixing copolymers and drugs in water at or above the critical micelle concentration (CMC), allowing them to self-assemble into micelles. While this method is straightforward, it typically results in low drug loading. To enhance loading, the temperature can be increased before adding the copolymer, or a thin film of the drug can be prepared before mixing.[67] [68]

Applications

1. Enhanced Bioavailability: Nanocarriers like nanoparticles, micelles, and nanoemulsions improve drug solubility and absorption through the corneal barrier, increasing bioavailability.
2. Prolonged Drug Retention: Nanowafers, liposomes, and cubosomes provide sustained drug release, reducing dosing frequency and enhancing therapeutic outcomes.
3. Improved Penetration: Dendrimers, nanoparticles, and micelles enhance drug

transport through tight junctions of the corneal epithelium.

4. Targeted Delivery: Dendrimers and liposomes enable precise drug delivery to intraocular tissues, reducing systemic side effects.
5. Controlled and Sustained Release: Nanoparticles, liposomes, and nanoemulsions provide controlled drug release and maintain therapeutic drug levels over time.
6. Enhanced Drug Stability: Niosomes and nanosuspensions protect drugs from degradation, improving drug stability and shelf life.
7. Reduced Inflammation and Infection: Nanocarriers enable effective delivery of anti-inflammatory (e.g., corticosteroids) and antibiotic drugs, reducing postoperative complications.
8. Minimized Side Effects: Controlled drug release and targeted delivery reduce toxicity and side effects associated with conventional eye drops.
9. Increased Patient Compliance: Nanowafers and liposomes reduce the need for frequent dosing, improving patient adherence.
10. Versatile Drug Loading: Cubosomes and dendrimers allow the loading of both hydrophilic and hydrophobic drugs, enhancing formulation flexibility.[69] [70] [71]

CONCLUSION

This review highlights the significant advancements and potential of nanoparticle-based drug delivery systems in the treatment of ocular diseases, particularly in post-cataract surgery management. Nanoparticles, including nanowafers, nanoemulsions, nanosuspensions, niosomes, liposomes, cubosomes, dendrimers, and micelles, have shown promising results in enhancing drug bioavailability, improving drug retention, and providing controlled and sustained drug release. Their ability to overcome ocular barriers and deliver drugs precisely to target tissues makes them highly effective in reducing inflammation, preventing infections, and promoting faster recovery post-surgery. Further research and clinical trials are essential to optimize these nanocarrier systems, ensuring their safety, efficacy, and long-term therapeutic success in ophthalmology.

REFERENCES

1. Cholkar K, Dasari SR, Pal D, Mitra AK. Eye: Anatomy, physiology and barriers to drug delivery. In: Ocular Transporters and Receptors: Their Role in Drug Delivery. Elsevier Ltd.; 2013. p. 1–36.
2. Nayak K, Misra M. A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother [Internet]. 2018;107(February):1564–82. Available from: https://doi.org/10.1016/j.biopha.2018.08.138
3. Faria MJ, González-Méijome JM, Real Oliveira MECD, Carracedo G, Lúcio M. Recent advances and strategies for nanocarrier-mediated topical therapy and theranostic for posterior eye disease. Adv Drug Deliv Rev. 2024;210(April).
4. DelMonte DW, Kim T. Anatomy and physiology of the cornea. J Cataract Refract Surg. 2011;37(3):588–98.
5. Nichols BA. Conjunctiva. Microsc Res Tech. 1996;33(4):296–319.
6. Fan X, Monnier VM, Whitson J. Lens glutathione homeostasis: Discrepancies and gaps in knowledge standing in the way of novel therapeutic approaches. Exp Eye Res [Internet]. 2017;156:103–11. Available from: http://dx.doi.org/10.1016/j.exer.2016.06.018
7. Cioffi CL. Introduction: Overview of the human eye, mammalian retina, and the retinoid visual cycle. Top Med Chem. 2020;35:1–42.
8. Sliney D, Wolbarsht M. Review of Anatomy and Physiology of the Eye and Skin. Saf with Lasers Other Opt Sources. 1980;65–100.
9. Malhotra A, Minja FJ, Crum A, Burrowes D. Ocular Anatomy and Cross-Sectional Imaging of the Eye. Semin Ultrasound, CT MRI [Internet]. 2011;32(1):2–13. Available from: http://dx.doi.org/10.1053/j.sult.2010.10.009
10. Abdelsalam A, Priore L Del, Zarbin MA. MAJOR REVIEW Drusen in Age-Related Macular Degeneration : Pathogenesis , Natural Course , and Laser Photocoagulation – Induced Regression. 1999;44(1).
11. David L. Stocum. Reegeneration of Neural Tissue. Regen Biol Med. 2012;2nd editio(ISBN 9780123848604):67–97.
12. Bishop PN. Molecular Composition of the Vitreous and Aging Changes. 2010;37–43.
13. Kels BD, Grzybowski A, Grant-Kels JM. Human ocular anatomy. Clin Dermatol [Internet]. 2015;33(2):140–6. Available from: http://dx.doi.org/10.1016/j.clindermatol.2014.10.006
14. Bertelli E. Anatomy of the eye and human visual system. Piccin; 2019. 452 p.
15. Feng K, You C, Yuan L. General Anatomy. In 2019. p. 3–30.
16. Lim JC, Vorontsova I, Martis RM, Donaldson PJ. Animal Models in Cataract Research [Internet]. Second Edi. Animal Models for the Study of Human

Disease: Second Edition. Elsevier Inc.; 2017. 103–116 p. Available from: http://dx.doi.org/10.1016/B978-0-12-809468-6/00004-8
17. Alshamrani AZ. Cataracts Pathophysiology and Managements. Egypt J Hosp Med. 2018;70(1):151–4.
18. Lam D, Rao SK, Ratra V, Liu Y, Mitchell P, King J, et al. Cataract. Nat Rev Dis Prim. 2015;1(June).
19. Young S, Sands J. Sun and the eye: Prevention and detection of light-induced disease. Clin Dermatol. 1998;16(4):477–85.
20. Medsinge A, Nischal KK. Pediatric cataract: Challenges and future directions. Clin Ophthalmol [Internet]. 2015;9:77–90. Available from: https://doi.org/10.2147/OPTH.S59009
21. Patel DK, Prasad SK, Kumar R, Hemalatha S. Cataract: A major secondary complication of diabetes, its epidemiology and an overview on major medicinal plants screened for anticataract activity. Asian Pacific J Trop Dis [Internet]. 2011;1(4):323–9. Available from: http://dx.doi.org/10.1016/S2222-1808(11)60075-3
22. Mamatha BS, Nidhi B, Padmaprabhu CA, Pallavi P, Vallikannan B. Risk factors for nuclear and cortical cataracts: A hospital based study. J Ophthalmic Vis Res. 2015;10(3):243–9.
23. Gupta V, Rajagopala M, Ravishankar B. Etiopathogenesis of cataract: An appraisal. Indian J Ophthalmol. 2014;62(2):103–10.
24. Liu YC, Wilkins M, Kim T, Malyugin B, Mehta JS. Cataracts. Lancet. 2017;390(10094):600–12.
25. Ismail R, Sallam A. Complications Associated with Cataract Surgery. In: Cataract Surgery. InTech; 2013.
26. Vasudevan S, Abraham A. Age Related or Senile Cataract: Pathology, Mechanism and Management. Austin J Clin Ophthalmol [Internet]. 2016;3(2). Available from: www.austinpublishinggroup.com
27. TOWNES CD, MORAN CT PH. Complication of cataract surgery. Am J Opthalmol. 1952 Sep;35(9):1311–9.
28. Daien V, Villain M. Complications of cataract surgery. Inter Bloc. 2017;36(4):218–9.
29. Asbell PA, Dualan I, Mindel J, Brocks D, Ahmad M, Epstein S. Age-related cataract. 2020;365:599–609.
30. Chan E, Mahroo OAR, Spalton DJ. Complications of cataract surgery. Clin Exp Optom. 2010;93(6):379–89.
31. Whitman MC, Vanderveen DK. Complications of pediatric cataract surgery. Semin Ophthalmol. 2014;29(5–6):414–20.
32. Maria Vittoria Cicinelli, John C Buchan, Maneck Nicholson, Varshini Varadaraj, Rohit C Khanna. Cataracts. Lancet. 2023;401(0140–6736):377–89.
33. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal Anti-inflammatory Drugs in Ophthalmology. Surv Ophthalmol [Internet]. 2010;55(2):108–33. Available from: http://dx.doi.org/10.1016/j.survophthal.2009.07.005
34. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J. 2008;10(2):229–41.
35. Colin J. The Role of NSAIDs in the Management of Postoperative Ophthalmic Inflammation. 2007;67(9):1291–308.
36. Hoffman RS, Braga-Mele R, Donaldson K, Emerick G, Henderson B, Kahook M, et al. Cataract surgery and nonsteroidal antiinflammatory drugs. J Cataract Refract Surg [Internet]. 2016;42(9):1368–79. Available from: http://dx.doi.org/10.1016/j.jcrs.2016.06.006
37. Pleyer U, Ursell PG, Rama P. Intraocular Pressure Effects of Common Topical Steroids for Post-Cataract Inflammation: Are They All the Same? Ophthalmol Ther. 2013;2(2):55–72.
38. Fung AT, Tran T, Lim LL, Samarawickrama C, Arnold J, Gillies M, et al. Local delivery of corticosteroids in clinical ophthalmology: A review. Clin Exp Ophthalmol. 2020;48(3):366–401.
39. Holmberg BJ, Maggs DJ. The use of corticosteroids to treat ocular inflammation. Vol. 34, Veterinary Clinics of North America - Small Animal Practice. 2004. p. 693–705.
40. Cholkar K, Patel SP, Vadlapudi AD, Mitra AK. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2013;29(2):106–23.
41. Lakhani P, Patil A, Majumdar S. Recent advances in topical nano drug-delivery systems for the anterior ocular segment. Ther Deliv. 2018;9(2):137–53.
42. Mofidfar M, Abdi B, Ahadian S, Mostafavi E, Desai TA, Abbasi F, et al. Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies. Int J Pharm [Internet]. 2021;607(May):120924. Available from: https://doi.org/10.1016/j.ijpharm.2021.120924
43. Weng Y, Liu J, Jin S, Guo W, Liang X, Hu Z. Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm Sin B [Internet]. 2017;7(3):281–91. Available from: http://dx.doi.org/10.1016/j.apsb.2016.09.001
44. Ahmed S, Amin MM, Sayed S. Ocular Drug Delivery: a Comprehensive Review. AAPS PharmSciTech [Internet]. 2023;24(2). Available from: https://doi.org/10.1208/s12249-023-02516-9
45. Patel A. Ocular drug delivery systems: An overview. World J Pharmacol. 2013;2(2):47.
46. Rawas-Qalaji M, Williams CA. Advances in ocular drug delivery. Curr Eye Res. 2012;37(5):345–56.
47. Reimondez-Troitiño S, Csaba N, Alonso MJ, De La Fuente M. Nanotherapies for the treatment of ocular diseases. Eur J Pharm Biopharm [Internet]. 2015;95:279–93. Available from: http://dx.doi.org/10.1016/j.ejpb.2015.02.019
48. Onugwu AL, Nwagwu CS, Onugwu OS, Echezona AC, Agbo CP, Ihim SA, et al. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases. J Control Release [Internet]. 2023;354(December 2022):465–88. Available from: https://doi.org/10.1016/j.jconrel.2023.01.018
49. Durgun ME, Güngör S, Özsoy Y. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases. J Ocul Pharmacol Ther.

2020;36(6):323–41.
50. Al Yabhouni SA, Mozumder MS, Hassan N, Mourad AHI, Issa MD TMA. Nanocarrier-Based, ocular drug delivery: Challenges, prospects, and the therapeutic landscape in the United Arab Emirates. Int J Pharm [Internet]. 2024;667(PB):124899. Available from: https://doi.org/10.1016/j.ijpharm.2024.124899
51. Rao BG, Mukherjee D, Reddy BM. Nanostructures for Novel Therapy NOVEL APPROACHES FOR PREPARATION OF NANOPARTICLES [Internet]. Nanostructures for Novel Therapy. Elsevier Inc.; 2017. 1–36 p. Available from: http://dx.doi.org/10.1016/B978-0-323-46142-9/00001-3
52. Mr Sharad Kamble, Miss Kaveri Bhosale, Mr Mahesh Mohite, Mrs Swapnali Navale. Methods of Preparation of Nanoparticles. Int J Adv Res Sci Commun Technol. 2023;7(4):121–7.
53. Mujoriya RZ, Dhamande K, Bodla RB. Niosomal drug delivery system - a review. Int J Appl Pharm. 2011;3(3):7–10.
54. Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon [Internet]. 2022;8(5):e09394. Available from: https://doi.org/10.1016/j.heliyon.2022.e09394
55. Yeo PL, Lim CL, Chye SM, Ling APK, Koh RY. Niosomes: A review of their structure, properties, methods of preparation, and medical applications. Asian Biomed. 2017;11(4):301–13.
56. Thabet Y, Elsabahy M, Eissa NG. Methods for preparation of niosomes: A focus on thin-film hydration method. Methods [Internet]. 2022;199(May 2021):9–15. Available from: https://doi.org/10.1016/j.ymeth.2021.05.004
57. Roy Biswas G, Biswas Majee S. Niosomes in ocular drug delivery Article in. Eur J Pharm Med Res [Internet]. 2017;813(March). Available from: www.ejpmr.com
58. Lakshmi P, Kumar GA. Nanosuspension technology: A review. Int J Pharm Pharm Sci. 2010;2(SUPPL. 4):35–40.
59. Kumar S, Burgess DJ. Long Acting Injections and Implants. Long Act Inject Implant. 2012;239–61.
60. Geetha G, Poojitha U, Arshad K, Khan A. Various Techniques for Preparation of Nanosuspension-A Review. Int J Pharma Res Rev IJPRR. 2014;3(39):30–7.
61. Borthakur P, Boruah PK, Sharma B, Das MR. 5 - Nanoemulsion: preparation and its application in food industry A2 - Grumezescu, Alexandru Mihai BT - Emulsions [Internet]. Nanotechnology in the Agri-Food Industry. Elsevier Inc.; 2016. 153–191 p. Available from: https://www.sciencedirect.com/science/article/pii/B9780128043066000052
62. Pagar KR, Darekar AB. Nanoemulsion: A new concept of Delivery System. Asian J Res Pharm Sci. 2019;9(1):39.
63. Bhatt P, Madhav S. A detailed review on oral mucosal drug delivery system. Int J Pharm Sci Res. 2011;2(10):2482-Anton, N., Vandamme, T. F. (2011). Nano-emu.
64. Gaballa S, El Garhy O, Abdelkader H. Cubosomes: composition, preparation, and drug delivery applications. J Adv Biomed Pharm Sci. 2019;0(0):0–0.
65. Sivadasan D, Sultan MH, Alqahtani SS, Javed S. Cubosomes in Drug Delivery—A Comprehensive Review on Its Structural Components, Preparation Techniques and Therapeutic Applications. Biomedicines. 2023;11(4).
66. Paramasivam G, Palem VV, Sundaram T, Sundaram V, Kishore SC, Bellucci S. Nanomaterials: Synthesis and applications in theranostics. Nanomaterials. 2021;11(12).
67. Mandal A, Bisht R, Rupenthal ID, Mitra AK. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J Control Release. 2017;248:96–116.
68. Li Z, Liu M, Ke L, Wang LJ, Wu C, Li C, et al. Flexible polymeric nanosized micelles for ophthalmic drug delivery: research progress in the last three years. Nanoscale Adv. 2021;3(18):5240–54.
69. Amrutkar CS, Patil SB. Review Article Nanocarriers for ocular drug delivery : Recent advances and future opportunities. 2023;
70. Gorantla S, Rapalli VK, Waghule T, Singh PP, Dubey SK, Saha RN, et al. Nanocarriers for ocular drug delivery : current status and translational opportunity. 2020;27835–55.
71. Li S, Chen L, Fu Y. Nanotechnology - based ocular drug delivery systems : recent advances and future prospects. J Nanobiotechnology [Internet]. 2023;1–39. Available from: https://doi.org/10.1186/s12951-023-01992-2